Paloian, Neil J. http://orcid.org/0000-0003-4945-9480
Nemeth, Blaise
Sharafinski, Mark
Modaff, Peggy
Steiner, Robert D.
Article History
Received: 4 October 2021
Revised: 26 January 2022
Accepted: 27 January 2022
First Online: 24 February 2022
Declarations
:
: Study approved by the University of Wisconsin-Madison Health Sciences Institutional Review Board.
: Waiver of informed consent granted by IRB.
: All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
: Neil Paloian is a member of the speaker’s bureau of Ultragenyx pharmaceuticals. Robert D. Steiner reports equity interest in and consulting fees from Acer Therapeutics and PTC Therapeutics. He also reports leading an investigator-initiated observational research study funded by Alexion via contract with Marshfield Clinic Health System, and consulting fees from Alexion, Best Doctors, E-Scape Bio, Health Advances, Precision for Value, and Travere, and honoraria from Medscape/WebMD and The France Foundation as well as employment with Prevention Genetics. The other authors have no relevant conflicts of interest or financial or proprietary interests to disclose.